Aria Pharmaceuticals
Aria Pharmaceuticals is a Palo Alto-based, privately held AI-driven biopharmaceutical company founded in 2014, using machine learning for drug discovery and supported by ~$14.3M in disclosed venture funding across 2015-2021.
- Company typePrivate
- Founded2014
- HeadquartersPalo Alto, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Aria Pharmaceuticals does
Aria Pharmaceuticals is a Palo Alto-based, privately held biopharmaceutical company founded in 2014 that positions itself as an AI-driven drug discovery organization. The company operates with a small team (11-50 employees) and is led by founder and CEO Andrew A. Radin, with operational leadership spanning discovery (Aaron Daugherty, VP Discovery), R&D (Mark Eller, SVP R&D), business development (Allen Poirson, SVP Biopharmaceutical BD), and human resources (Melissa Horton, Head of HR). The website (ariapharmaceuticals.com) is currently inaccessible, limiting direct verification of pipeline details, platform architecture, or program status.
The company has raised approximately $14.3M across four disclosed funding rounds between 2015 and 2021, anchored by top-tier venture capital. Andreessen Horowitz led the 2015 seed ($3.4M) alongside CLI Ventures and StartX (Stanford-StartX Fund), then participated in the 2018 Series A ($10M) led by SBVA with OS Fund. A 2021-07-09 round added undisclosed capital from Future Planet Capital, Network.VC, and Silicon Valley Syndicate Club. No product launches, partnerships, acquisitions, or licensing deals are documented in the available source material.
Given the small headcount, total disclosed funding in the low-teens of millions, absence of customer logos or partnership disclosures, and R&D-stage leadership composition, Aria's business model is consistent with a preclinical AI-drug-discovery platform that would monetize through pharma collaborations, out-licensing deals, or milestone-based partnerships rather than product sales. Specific pricing, revenue mechanics, customer segments, and pipeline indications cannot be verified from the supplied data.
Aria Pharmaceuticals firmographics
Firmographics- Name
- Aria Pharmaceuticals
- Website
- https://ariapharmaceuticals.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Aria Pharmaceuticals is a Palo Alto-based, privately held AI-driven biopharmaceutical company founded in 2014, using machine learning for drug discovery and supported by ~$14.3M in disclosed venture funding across 2015-2021.
- Ownership category
- akta.pro rank
Aria Pharmaceuticals industry classification
Industry- Product category
- Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM)
Keywords
Where Aria Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Markets served
Aria Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Aria Pharmaceuticals product offering
Product offeringCore offering
Aria Pharmaceuticals is an AI-driven biopharmaceutical company focused on discovering and developing new therapeutic drug candidates using machine learning and computational approaches. The company applies artificial intelligence to accelerate the identification and optimization of novel compounds for pharmaceutical applications. Its operations center on AI-enabled preclinical drug discovery research rather than the manufacture or sale of marketed pharmaceutical products.
Differentiator
Problem solved
Functional benefit
Products and services
- AI-driven drug discovery programs
Companies that use Aria Pharmaceuticals
Customer profileIdeal customer profiles1 record
Aria Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Aria Pharmaceuticals partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights3 records
Aria Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Insitro: Machine-learning-driven drug discovery company combining induced pluripotent stem cell biology with AI models. Insitro directly parallels Aria's positioning as an AI-native biopharma pursuing both partnered and internal programs.
- BenevolentAI: AI-driven drug discovery company using knowledge graphs and ML to identify novel targets and therapeutics. BenevolentAI is a directly comparable AI-biopharma with both partnered programs and an internal pipeline, similar in commercial model to Aria.
- Recursion Pharmaceuticals: AI-driven biopharma combining high-throughput biology with ML to discover therapeutics. Like Aria, Recursion is a small-molecule-focused platform player using computational methods to identify novel targets and drug candidates for pharma partners and internal pipelines.
- Atomwise: AI-driven small-molecule drug discovery company using structure-based deep learning to identify novel compounds. Atomwise operates a partnership-heavy model closely aligned with how an AI-platform biopharma like Aria monetizes its technology.
- Exscientia: AI-driven precision medicine company that uses its platform to design and develop small-molecule therapeutics. Direct competitor to Aria in AI-first small-molecule drug design and pharma partnership model.
Broad incumbents
- Schrödinger: Computational chemistry and materials science platform with a therapeutics arm. Schrödinger is a broader, more established incumbent that uses physics-based modeling and ML for drug discovery — comparable to Aria's computational approach but with much greater scale and a public-market profile.
- Isomorphic Labs: Alphabet-backed AI drug discovery company applying DeepMind's protein-structure and generative models to pharma. Represents the well-capitalized end of Aria's competitive set and a potential partner or acquirer of smaller AI-platform biopharmas.
Emerging players
- Iambic Therapeutics: AI-driven drug discovery company that combines physics-based modeling with ML to design differentiated small molecules. Iambic is a comparable emerging platform player competing in the same AI-first therapeutic discovery category as Aria.
- Cradle Bio: AI platform for protein and biologics engineering. Cradle extends AI-driven discovery into biologics design — adjacent to Aria's discovery ambitions and a useful comparable for how lean AI-platform teams monetize through partnerships.
- XtalPi: AI- and quantum-physics-driven drug discovery and crystal-form prediction company. XtalPi combines computational and experimental platforms to identify small molecules — overlapping with Aria's AI-driven biopharma approach.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
Aria Pharmaceuticals social profiles
Digital presenceAria Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aria Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles5 records
Aria Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aria Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aria Pharmaceuticals
What does Aria Pharmaceuticals do?
Aria Pharmaceuticals is an AI-driven biopharmaceutical company focused on discovering and developing new therapeutic drug candidates using machine learning and computational approaches. The company applies artificial intelligence to accelerate the identification and optimization of novel compounds for pharmaceutical applications. Its operations center on AI-enabled preclinical drug discovery research rather than the manufacture or sale of marketed pharmaceutical products.
When was Aria Pharmaceuticals founded?
Aria Pharmaceuticals was founded in 2014. It employs 11 to 50 people.
Where is Aria Pharmaceuticals based?
Aria Pharmaceuticals is headquartered in Palo Alto, United States, in the North America region.
Who are Aria Pharmaceuticals's main competitors?
Direct peers on record are Insitro, BenevolentAI, Recursion Pharmaceuticals, Atomwise and Exscientia. Broad incumbents are Schrödinger and Isomorphic Labs. Emerging players are Iambic Therapeutics, Cradle Bio and XtalPi.
Does Aria Pharmaceuticals have an API?
No public API is recorded for Aria Pharmaceuticals.
What industry is Aria Pharmaceuticals in?
Aria Pharmaceuticals's product category is Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 8731.